首页> 外国专利> AMINOPYRIMIDINE DERIVATIVES AS LEUCINE-RICH REPEAT KINASE 2 (LRRK2) MODULATORS

AMINOPYRIMIDINE DERIVATIVES AS LEUCINE-RICH REPEAT KINASE 2 (LRRK2) MODULATORS

机译:氨基嘧啶衍生物作为富含亮氨酸的重复激酶2(LRRK2)调节剂。

摘要

FIELD: chemistry.;SUBSTANCE: in the general formula I I, A is a five-, six- or seven-membered saturated or unsaturated ring, that includes one or two heteroatoms selected from O and N, which is substituted once with R5 and which is optionally substituted one, two or three times with R6 groups; X is -NRa-, wherein Ra is hydrogen; R1 is C1-6alkyl; R2 is halogen, C1-6alkoxy, cyano or halo-C1-6alkyl; one of the groups R3 and R4 is halogen, C1-6alkyl or C1-6alkoxy, and the other group is hydrogen; R5 is oxo, C1-6alkyl, C3-6cycloalkyl or -C (O) -NRbRc, where each of the Rb and Rc is independently hydrogen or C1-6alkyl, or Rb and Rc together with atoms, to which they are attached, can form a 4-6-membered saturated heterocyclyl, which optionally comprises an additional heteroatom selected from O and N, and which is optionally substituted once with R6; or Rb and Rc together with the atoms to which they are attached, can form 2-oxa-5-azabicyclo [2.2.1] heptanyl; and each group R6 is independently C1-6alkyl, C3-6cycloalkyl, halogen, hydroxy-C1-6alkyl, C1-6alkoxy-C1-6alkyl or 4-6-membered saturated heterocyclyl with oxygen as a heteroatom. Preferable compound is a compound corresponding the formula IIa or IIb ; where m is 0; 1 or 2; Z is -C (R7)2-; -NR8- or -O-; each group R7 is independently hydrogen or C1-6alkyl; and each group R8 is independently hydrogen, C1-6alkyl, C3-6cycloalkyl, halogen, hydroxy-C1-6alkyl, C1-6alkoxy-C1-6alkyl or 4-6-membered saturated heterocyclyl with oxygen as a heteroatom.;EFFECT: invention relates to a novel compound of formula I or a pharmaceutically acceptable salt thereof, which possess the properties of the LRRK2 inhibitor and can be used to prevent or treat Parkinson's disease.;22 cl, 3 tbl, 13 ex
机译:领域:化学。;实质:在通式I中 I,A是一个五,是六元或七元饱和或不饱和环,包括一个或两个选自O和N的杂原子,被R 5 取代一次,并可选地被R 5 取代R 6 组; X为-NR a -,其中R a 为氢; R 1 是C 1-6 烷基; R 2 是卤素,C 1-6 烷氧基,氰基或卤代-C 1-6 烷基; R 3 和R 4 中的一个是卤素,C 1-6 烷基或C 1-6 烷氧基,另一个基团是氢; R 5 是氧代,C 1-6 烷基,C 3-6 环烷基或-C(O)-NR b < / Sup> R c ,其中每个R b 和R c 分别为氢或C 1-6 烷基或R b 和R c 与它们所连接的原子一起可以形成4-6元饱和杂环基,该杂环基可任选包含一个额外的杂原子选自O和N,并且任选被R 6 取代一次;或R b 和R c 与它们所连接的原子一起可以形成2-oxa-5-氮杂双环[2.2.1]庚基;并且每个基团R 6 独立地为C 1-6 烷基,C 3-6 环烷基,卤素,羟基-C 1-氧为杂原子的6 烷基,C <Sub> 1-6 烷氧基-C <Sub> 1-6 烷基或4-6元饱和杂环基。优选的化合物是对应于式IIa或IIb的化合物; 其中m为0; 1或2; Z是-C(R 7 2 -; -NR 8 -或-O-;每个基团R 7 独立地是氢或C 1-6 烷基;并且每个基团R 8 独立地是氢,C 1-6 烷基,C 3-6 环烷基,卤素,羟基-C 1-6 烷基,C 1-6 烷氧基-C 1-6 烷基或以氧为杂原子的4-6元饱和杂环基;效果:本发明涉及具有LRRK2抑制剂的性质并且可以用于预防或治疗帕金森氏病的式I的新型化合物或其药学上可接受的盐。; 22 cl,3 tbl,13 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号